Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab plus neoadjuvant chemoradiotherapy for locally advanced rectal cancer
ChiCTR2000040318Phase 2Not yet recruiting
- Sponsor
- Xuzhou Central Hospital
- Start
- Dec 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab in rectal adenocarcinoma, sponsored by Xuzhou Central Hospital. Primary endpoint: pathologic complete response. Planned start Dec 2020; status: not yet recruiting.
02
Drugs
sintilimab
03
Conditions
rectal adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2000040318.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000040318.